Angiographic Adverse Events, Creatine Kinase-MB Elevation, and Ischemic End Points Complicating Percutaneous Coronary Intervention (a REPLACE-2 Substudy)

American Journal of Cardiology

Volumn 97, Issue 11, 2006, Pages 1591-1596

  Blankenship, James C ^a   Haldis, Tom ^a   Feit, Frederick ^b   Hu, Tingfei ^c   Kleiman, Neal S ^d   Topol, Eric J ^c   Lincoff, A Michael ^c  

^a GEISINGER MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE;

ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; CORONARY STENT; DEATH; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 33646699603     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.12.050     Document Type: Article

References (30)

1. Kugelmass A.D., Cohen D.J., Moscucci M., Piana R.N., Senerchia C., Kuntz R.E., and Baim D.S. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 74 (1994) 748-754
2. Tardiff B.E., Califf R.M., Tcheng J.E., Lincoff A.M., Sigmon K.N., Harrington R.A., Mahaffey K.W., Ohman E.M., Teirstein P.S., Blankenship J.C., et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 33 (1999) 88-96
3. Kini A., Kini S., Marmur J.D., Bertea T., Dangaas G., Cocke T.P., and Sharma S.K. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Cath Cardiovasc Intervent 48 (1999) 123-129
4. Mehran R., Dangas G., Mintz G.S., Lansky A.J., Pichard A.D., Satler L.F., Kent K.M., Stone G.W., and Leon M.B. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions. Circulation 101 (2000) 604-610
5. Saucedo J.F., Mehran R., Dangas G., Hong M.K., Lansky A., Kent K.M., Satler L.F., Pichard A.D., Stone G.W., and Leon M.B. Long-term clinical events following creatine-kinase myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 35 (2000) 1134-1141
6. Abdelmeguid A.E., Topol E.J., Whitlow P.L., Sapp S.K., and Ellis S.E. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 94 (1996) 1528-1536
7. Kong T.Q., Davidson C.J., Meyers S.N., Tauke J.T., Parker M.A., and Bonow R.O. Prognostic implications of creatine kinase elevation following elective coronary interventions. JAMA 227 (1997) 461-466
8. Brener S.J., Lytle B.W., Schneider J.P., Ellis S.G., and Topol E.J. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 40 (2002) 1961-1967
9. Blankenship J.C., Sigmon K.N., Pieper K.S., O'Shea C.O., Tardiff B.E., and Tcheng J.E. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II trial. Am J Cardiol 88 (2001) 969-973
10. Blankenship J.C., Tasisssa G., O'Shea J.C., Iliadis E.A., Bachour F.A., Cohen D.J., Lui H.K., Mann T., Cohen E., and Tcheng J.E. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 38 (2001) 653-658
11. Islam M.A., Blankenship J.C., Balog C., Iliadis E.A., Lincoff A.M., Tcheng J.E., Califf R.M., and Topol E.J. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa inhibition in Stenting Trial (EPISTENT). Am J Cardiol 90 (2002) 916-921
12. Klein L.W., Kramer B.L., Howard E., and Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 17 (1991) 621-626
13. Fuchs S., Kornowski R., Mehran R., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Clark C.E., Stone G.W., and Leon M.B. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 85 (2000) 1077-1082
14. Stone G.W., Roxana M., Dangas G., Lansky A.J., Kornowski R., and Leon M.B. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous interventions. a device specific analysis of 7147 patients. Circulation 104 (2001) 642-647
15. Schuepp M., Ullmer E., Weinbacher M., Pfisterer M., Scholer A., Ritz R., and Rickenbacher R. Chest pain early after percutanous coronary intervention. incidence and relation to ECG changes, cardiac enzymes and follow-up events. J Invas Cardiol 13 (2001) 211-216
16. Ellis S.G., Brener S.J., Lincoff A.M., Moliterno D.J., Whitlow P.L., Schneider J.P., and Topol E.J. Beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise. Circulation 104 (2001) 2685-2688
17. Cantor W.J., Newby L.K., Christenson R.H., Tuttle R.H., Hasselblad V., Armstrong P.W., Moliterno D.J., Califf R.M., Topol E.J., and Ohman E.M. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 39 (2002) 1738-1744
18. Brener S.J., Ellis S.G., Schneider J., and Topol E.J. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 23 (2002) 869-876
19. Ohman E.M., and Tardiff B.E. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. JAMA 227 (1997) 495-497
20. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 289 (2003) 853-863
21. Lincoff A.M., Kleiman N.S., Kereiakes D.J., Feit F., Bitl J.A., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al., REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization. JAMA 292 (2004) 696-703
22. Ross M.J., Hermann H.C., Moliterno D.J., Blankenship J.C., Demopoulos L., DiBattiste P.M., Ellis S.G., Ghazzal Z., Martin J.L., White J., and Topol E.J. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 42 (2003) 981-988
23. Blankenship J.C., Islam A., Wood C.G., and Iliadis E.A. Angiographic adverse outcomes during percutaneous coronary intervention fail to predict creatine kinase-MB elevation. Catheter Cardiovasc Interv 63 (2004) 31-41
24. Abdelmeguid A.E., and Topol E.J. The myth of the myocardial "infarctlet" during percutaneous coronary revascularization procedures. Circulation 94 (1996) 3369-3375
25. Abdelmeguid A.E., Ellis S.G., Sapp S.K., Whitlow P.L., and Topol E.J. Defining the appropriate threshold of creatinine kinase elevation after percutaneous coronary intervention. Am Heart J 131 (1996) 1097-1105
26. Harrington R.A., Lincoff A.M., Califf R.M., Holmes D.R., Berdan L.G., O'Hanesian M.A., Keeler G.P., Garratt K.N., Ohman E.M., Mark D.B., et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention. insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 25 (1995) 1693-1699
27. Ellis S.G., Chew D., Chan A., Whitlow P.L., Schneider J.P., and Topol E.J. Death following creatine kinase-MB elevation after coronary intervention. Circulation 106 (2002) 1205-1210
28. Akkerhuis K.M., Alexander J.H., Tardiff B.E., Boersma E., Harrington R.A., Lincoff A.M., and Simoons M.L. Minor myocardial damage and prognosis. Circulation 105 (2002) 554-556
29. Ricciardi M.J., Wu E., Davidson C.J., Choi K.M., Klocke F.J., Bonow R.O., Judd R.M., and Kim R.J. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 103 (2001) 2780-2783
30. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 36 (2000) 959-969